Elcin Zan, MD

To evaluate the doses to the bone marrow and kidneys from Lu-177 radiopharmaceutical therapy (RPT), as affected by radiopharmaceutical type, cycle of administration, and tumor volume.

To develop an automated tool for tumor segmentation, identification, dosimetry, and response assessment for radiopharmaceutical therapy (RPT).